Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kronos Bio Inc (KRON)

Kronos Bio Inc (KRON)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,795
  • Shares Outstanding, K 60,094
  • Annual Sales, $ 6,290 K
  • Annual Income, $ -112,670 K
  • 60-Month Beta 1.77
  • Price/Sales 9.65
  • Price/Cash Flow N/A
  • Price/Book 0.47
Trade KRON with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.99
  • Most Recent Earnings $-0.50 on 05/09/24
  • Next Earnings Date 08/13/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 406.06% ( +71.94%)
  • Historical Volatility 139.99%
  • IV Percentile 85%
  • IV Rank 26.23%
  • IV High 1,466.97% on 03/15/24
  • IV Low 28.89% on 07/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 121
  • Volume Avg (30-Day) 42
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 3,354
  • Open Int (30-Day) 3,542

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.36
  • Number of Estimates 3
  • High Estimate -0.25
  • Low Estimate -0.42
  • Prior Year -0.52
  • Growth Rate Est. (year over year) +30.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.7151 +34.32%
on 06/07/24
1.3300 -27.78%
on 06/13/24
+0.2048 (+27.10%)
since 05/24/24
3-Month
0.6900 +39.20%
on 05/24/24
1.3800 -30.40%
on 04/01/24
-0.2295 (-19.29%)
since 03/26/24
52-Week
0.6900 +39.20%
on 05/24/24
2.2900 -58.06%
on 07/13/23
-0.5995 (-38.43%)
since 06/26/23

Most Recent Stories

More News
5 Microcap Stocks With 65% or More Upside Potential

While they do carry higher-than-average risk, these microcaps also offer major upside potential for investors seeking startup-sized returns.

BTBT : 3.46 (+2.06%)
^BTCUSD : 61,190.08 (-1.15%)
ERJ24 : 3,144.04s (-0.63%)
GOEV : 1.8850 (+16.36%)
KRON : 0.9704 (+2.68%)
OGI : 1.5350 (+3.02%)
QBTS : 1.0500 (-3.67%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/PRNewswire/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider...

KRON : 0.9704 (+2.68%)
Kronos Bio and Invivoscribe Partner on Companion Diagnostic for Use with Entospletinib, Kronos Bio's Investigational Compound Being Developed for Patients with AML

/CNW/ -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of...

KRON : 0.9704 (+2.68%)
Kronos Bio Continues to Advance Investigational SYK Inhibitors Entospletinib and Lanraplenib with New Preclinical Data at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents suggesting evidence of preclinical anti-tumor activity in acute...

KRON : 0.9704 (+2.68%)
Kronos Bio’s Investigational SYK Inhibitors Entospletinib and Lanraplenib to be Featured in Four Poster Presentations at EHA2022 Congress

Posters include preclinical data on SYK inhibition in combination with targeted agents and demonstrate preclinical anti-tumor activity in acute myeloid...

KRON : 0.9704 (+2.68%)
Will Insiders Be Tempted To Buy More KRON At The New 52-Week Low?

In trading on Thursday, shares of Kronos Bio Inc touched a new 52-week low of $6.04/share. That's a $22.38 share price drop, or -78.75% decline from the 52-week high of $28.42 set back on 06/08/2021....

KRON : 0.9704 (+2.68%)
Kronos Bio Presents Preclinical Data on Oral CDK9 Inhibitor KB-0742, Providing Additional Evidence of Potential Efficacy in MYC-Amplified and Transcriptionally Addicted Tumors at AACR

Preclinical data featured in three posters show potential of KB-0742 in triple-negative breast, lung and ovarian cancers, as well as lymphoma and rare,...

KRON : 0.9704 (+2.68%)
Kronos Bio’s Investigational CDK9 Inhibitor KB-0742 to be Featured in Four Preclinical Poster Presentations at American Association for Cancer Research Annual Meeting 2022

Data include results from preclinical studies of KB-0742 in MYC-amplified cancers, including small-cell lung, triple-negative breast and ovarian, as well...

KRON : 0.9704 (+2.68%)
Kronos Bio is Now Oversold (KRON)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical...

KRON : 0.9704 (+2.68%)
Kronos Bio Announces Participation in Cowen 42nd Annual Health Care Conference

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 01, 2022 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives...

KRON : 0.9704 (+2.68%)

Business Summary

Kronos Bio Inc. is a clinical-stage biopharmaceutical company. It engages in discovery and development of novel cancer therapeutics designed to transform patient outcomes by targeting dysregulated transcription. Kronos Bio Inc. is headquartered in San Mateo, Calif.

See More

Key Turning Points

3rd Resistance Point 1.2050
2nd Resistance Point 1.1525
1st Resistance Point 1.0488
Last Price 0.9704
1st Support Level 0.8926
2nd Support Level 0.8401
3rd Support Level 0.7364

See More

52-Week High 2.2900
Fibonacci 61.8% 1.6788
Fibonacci 50% 1.4900
Fibonacci 38.2% 1.3012
Last Price 0.9704
52-Week Low 0.6900

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar